Recruiting
T-DXd
Lung Cancer
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Trial #: NCT06809764
Recruiting
T-DXd
Phase 3 Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Trial #: NCT06899126
Recruiting
T-DXd
Phase 3 Tumor-agnostic
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Trial #: NCT06174987
Recruiting
T-DXd
Phase 2 Gastric Cancer
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Trial #: NCT04379596
Recruiting
Edoxaban
Phase 4 Cardiovascular - AF
Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)
Trial #: NCT06402851
Recruiting
I-DXd
Phase 1 Phase 2 Tumor-agnostic
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Trial #: NCT04145622
Recruiting
Quizartinib
Phase 1 Hematology
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Trial #: NCT06740799
Pages: 1  2  3  4  5  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.